Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy

Assiut University

Status: Unknown

Conditions: Diabetic Nephropathies

Treatments: Diagnostic Test: serum immunoglobulin G level

Study type: Interventional

Funder types: Other

Identifiers

NCT03212755

PRUD

Details and patient eligibility

About

Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . Diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries Diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation

Enrollment: 75 estimated patients

Sex: All

Ages: 30 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• type 2 diabetic patients

Exclusion criteria

• patients with diabetes type 1 ,
• pregnant and lactating females ,
• patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .

Trial design

Primary purpose: Screening

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

75 participants in 3 patient groups

group 1

Experimental group

Description:

25 diabetic patients without diabetic nephropathy

Treatment:

Diagnostic Test: serum immunoglobulin G level

group 2

Experimental group

Description:

25 type 2 diabetic patients with diabetic nephropathy

Treatment:

Diagnostic Test: serum immunoglobulin G level

group 3

Sham Comparator group

Description:

25 healthy subjects

Treatment:

Diagnostic Test: serum immunoglobulin G level